title: Bilateral episcleritis as a manifestation of cutaneous leukocytoclastic vasculitis.
abstract: OBJECTIVE
  The authors describe how bilateral episcleritis can be a sign of active systemic disease and can respond to treatment in a patient with cutaneous leukocytoclastic vasculitis.
  
  
  METHODS
  Case report.
  
  
  METHODS
  Comprehensive ophthalmic and physical examination and color photography were used to monitor inflammation and its response to systemic immunosuppression.
  
  
  RESULTS
  Systemic cyclophosphamide caused regression of systemic symptoms, cutaneous lesions, and episcleritis. After an 8-month follow-up, the patient has not had a systemic or ocular recurrence.
  
  
  CONCLUSIONS
  Episcleritis may be a manifestation of cutaneous leukocytoclastic vasculitis. Careful examination of ocular inflammation is important in monitoring systemic disease and treatment.
authors.affiliation: Cleveland Clinic Foundation, Cole Eye Institute, Cleveland, Ohio, USA.
authors.forename: K
authors.initials: K
authors.lastname: Bollinger
authors.forename: C
authors.initials: C
authors.lastname: Medina
authors.forename: V L
authors.initials: VL
authors.lastname: Perez
mesh_terms: D000368:Aged; D003520:Cyclophosphamide / Q000627:therapeutic use; D007839:Functional Laterality; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D015423:Scleritis / Q000175:diagnosis* / Q000188:drug therapy; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000175:diagnosis* / Q000188:drug therapy
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate